文献速递肿瘤 PET/CT放射性药物与辐射防护

临床前评估[18F]FB-A20FMDV2作为选择性标记物用于啮齿类动物肺内αVβ6整合素占位正电子发射断层显像测量

Preclinical evaluation of [18F]FB-A20FMDV2 as a selective marker for measuring αVβ6 integrin occupancy using positron emission tomography in rodent lung.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-01-03

本研究采用全自动GMP compliant工艺合成[18F]FB-A20FMDV2,在大鼠中开展同源和异源阻断实验,并用OLINDA/EXM软件估算剂量。结果显示该示踪剂合成时间180分钟,放化纯度>97%,30-60分钟肺/心SUV比值在同源阻断中降低38.9±6.9%、异源阻断中降低56±19.2%,估算人体全身有效剂量为33.5 μSv/MBq。结论认为该配体可选择性测量肺内αvβ6整合素占位,支持临床转化研究。

要点

  • [18F]FB-A20FMDV2经全自动GMP compliant工艺合成,放化纯度>97%,摩尔活度高达150 GBq/μmol。
  • 大鼠同源阻断使30-60分钟肺/心SUV比值降低38.9±6.9%,异源阻断降低56±19.2%。
  • 基于啮齿类动物数据估算人体全身有效剂量为33.5 μSv/MBq。

核心结论

  • [18F]FB-A20FMDV2是一种特异、选择性的PET配体,可用于测量肺内药物相关的αvβ6整合素占位。
  • 从啮齿类动物数据外推的有效剂量与典型氟-18标记化合物相当,结合新型全自动GMP compliant合成工艺,允许用于转化研究的临床使用。

研究设计与样本

  • 本研究为临床前评估,采用Sprague-Dawley大鼠进行同源(未标记FB-A20FMDV2)和异源(抗αvβ6抗体8G6)阻断实验。
  • [18F]FB-A20FMDV2的合成采用全自动GMP compliant工艺。
  • 为生成剂量估算,计算组织驻留时间,并使用OLINDA/EXM软件计算组织暴露和有效剂量。

主要发现

  • [18F]FB-A20FMDV2合成耗时180分钟,提供约800 MBq产物,摩尔活度高达150 GBq/μmol,放化纯度>97%。
  • 大鼠静脉给药后,[18F]FB-A20FMDV2快速代谢,30分钟时完整示踪剂占血浆总放射性的5%。
  • 给药后30-60分钟,同源阻断使肺/心SUV比值降低38.9±6.9%,异源阻断降低56±19.2%。
  • 基于OLINDA/EXM的啮齿类动物生物分布和剂量计算,估算人体全身有效剂量为33.5 μSv/MBq。

关键数值与推荐

  • [18F]FB-A20FMDV2的摩尔活度高达150 GBq/μmol,放化纯度>97%。
  • 同源阻断后30-60分钟肺/心SUV比值降低38.9±6.9%,异源阻断后降低56±19.2%。
  • 估算人体全身有效剂量为33.5 μSv/MBq。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Integrin αvβ6 belongs to the RGD subset of the integrin family, and its expression levels are a prognostic and theranostic factor in some types of cancer and pulmonary fibrosis. This paper describes the GMP radiolabelling of the synthetic 20 amino acid peptide A20FMDV2 (NAVPNLRGDLQVLAQKVART), derived from the foot-and-mouth disease virus, and characterises the use of [18F]FB-A20FMDV2 as a high affinity, specific and selective PET radioligand for the quantitation and visualisation of αvβ6 in rodent lung to support human translational studies. METHODS: The synthesis of [18F]FB-A20FMDV2 was performed using a fully automated and GMP-compliant process. Sprague-Dawley rats were used to perform homologous (unlabelled FB-A20FMDV2) and heterologous (anti-αvβ6 antibody 8G6) blocking studies. In order to generate a dosimetry estimate, tissue residence times were generated, and associated tissue exposure and effective dose were calculated using the Organ Level Internal Dose Assessment/Exponential Modelling (OLINDA/EXM) software. RESULTS: [18F]FB-A20FMDV2 synthesis was accomplished in 180 min providing ~800 MBq of [18F]FB-A20FMDV2 with a molar activity of up to 150 GBq/μmol and high radiochemical purity (> 97%). Following i.v. administration to rats, [18F]FB-A20FMDV2 was rapidly metabolised with intact radiotracer representing 5% of the total radioactivity present in rat plasma at 30 min. For the homologous and heterologous block in rats, lung-to-heart SUV ratios at 30-60 min post-administration of [18F]FB-A20FMDV2 were reduced by 38.9 ± 6.9% and 56 ± 19.2% for homologous and heterologous block, respectively. Rodent biodistribution and dosimetry calculations using OLINDA/EXM provided a whole body effective dose in humans 33.5 μSv/MBq. CONCLUSION: [18F]FB-A20FMDV2 represents a specific and selective PET ligand to measure drug-associated αvβ6 integrin occupancy in lung. The effective dose, extrapolated from rodent data, is in line with typical values for compounds labelled with fluorine-18 and combined with the novel fully automated and GMP-compliant synthesis and allows for clinical use in translational studies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Onega M, Parker CA, Coello C, et al. Preclinical evaluation of [18F]FB-A20FMDV2 as a selective marker for measuring αVβ6 integrin occupancy using positron emission tomography in rodent lung. Eur J Nucl Med Mol Imaging. 2020. PMID: 31897589. doi:10.1007/s00259-019-04653-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。